Market research
7IN.F Intersect ENT, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 920M
- P/E ratio
- Not available
- Analyst target
- 25.21
- Dividend yield
- 0.0%
- Beta
- 1.53
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 920M
- P/E ratio
- Not available
- Analyst target
- 25.21
- Dividend yield
- 0.0%
- Beta
- 1.53
About
About Intersect ENT, Inc
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California. As of May 13, 2022, Intersect ENT, Inc. operates as a subsidiary of Medtronic plc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 7IN.F discussion.
5 years, 5 months ago
Intersect ENT, Inc is currently in a long term downtrend where the price is trading 5.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.3.
Intersect ENT, Inc's total revenue sank by 11.1% to $28M since the same quarter in the previous year.
Its net income has dropped by 153.8% to $-20M since the same quarter in the previous year.
Finally, its free cash flow fell by 28.4% to $-11M since the same quarter in the previous year.
Based on the above factors, Intersect ENT, Inc gets an overall score of 1/5.